22-499 Phase I
An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given orally as monotherapy in patients with unresectable metastatic KRAS wild type amplified gastric, oesophageal, and gastroesophageal-junction adenocarcinoma
Phase II Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer